1-800-887-8100
COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
MENU
Shared Solutions®
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

How COPAXONE® is thought to work

Lymph node and bloodstream diagramLymph node and bloodstream diagramLymph Node and Bloodstream Diagram
Periphery
Lymph node
Lymph Node
Bloodstream
Bloodstream
Lymph node and bloodstream diagram
Naive T cells
Lymph node and bloodstream diagram
Proinflammatory Th1 cells (MS-specific)
Lymph node and bloodstream diagram
Anti-inflammatory Th2 cells (MS-specific)
Periphery
A proven mix of efficacy, safety, and tolerability in relapsing forms of MS
SEE STUDY RESULTS
Learn about a demonstrated safety and tolerability profile
Review safety profile
Explore milestones in the development of COPAXONE® as an enduring option in relapsing MS care.
VIEW OUR TIMELINE

References

  1. COPAXONE® (glatiramer acetate injection) prescribing information. Rev. 8/2016. Teva Neuroscience, Inc.
  2. Schellekens H, Klinger E, Muhlebach S, et al. Regul Toxicol Pharmacol. 2011;59(1):176-183.
  3. Johnson KP. Expert Opin Drug Metab Toxicol. 2010;6(5):643-660.

RRMS, relapsing-remitting multiple sclerosis.


Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

IMPORTANT SAFETY INFORMATION

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site
×